Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352313 · ClinicalTrials.gov registry record · Phase 1
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT00352313 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 82 participants.
The verdict
NCT00352313, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
RATIONALE: ATN-161 may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ATN-161 together with carboplatin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of ATN-161 when given together with carboplatin and to see how well they work in treating patients with recurrent malignant glioma.
Interventions
- DRUG carboplatin
- DRUG ATN-161
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352313
The ClinicalTrials.gov registry entry for NCT00352313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT00352313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352313 about?
NCT00352313 is a clinical study titled "ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma". RATIONALE: ATN-161 may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ATN-161 together with carboplati...
What is the current status of trial NCT00352313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2006-05. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00352313?
The interventions under investigation include: carboplatin (DRUG), ATN-161 (DRUG).
Who is sponsoring clinical trial NCT00352313?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.